Jump Financial LLC Buys Shares of 28,996 MBX Biosciences, Inc. $MBX

Key Points

• Jump Financial LLC has purchased 28,996 shares of MBX Biosciences, Inc. valued at approximately $214,000, representing about 0.09% of the company.
• The stock price of MBX Biosciences has decreased by 10.3%, and currently trades at $12.92, with a market capitalization of $434.03 million.
• Analysts have indicated a positive outlook for MBX Biosciences, with multiple reports rating it as a "Buy" and a consensus target price of $37.63.

Jump Financial LLC bought a new position in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 28,996 shares of the company's stock, valued at approximately $214,000. Jump Financial LLC owned 0.09% of MBX Biosciences at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Driehaus Capital Management LLC grew its holdings in MBX Biosciences by 61.2% in the 4th quarter. Driehaus Capital Management LLC now owns 1,581,760 shares of the company's stock valued at $29,152,000 after buying an additional 600,438 shares in the last quarter. Woodline Partners LP grew its holdings in MBX Biosciences by 17.1% in the 4th quarter. Woodline Partners LP now owns 608,721 shares of the company's stock valued at $11,219,000 after buying an additional 89,046 shares in the last quarter. Citadel Advisors LLC grew its holdings in MBX Biosciences by 62.5% in the 4th quarter. Citadel Advisors LLC now owns 220,330 shares of the company's stock valued at $4,061,000 after buying an additional 84,722 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new position in MBX Biosciences in the 4th quarter valued at $3,133,000. Finally, TD Asset Management Inc grew its holdings in MBX Biosciences by 313.9% in the 1st quarter. TD Asset Management Inc now owns 151,504 shares of the company's stock valued at $1,118,000 after buying an additional 114,904 shares in the last quarter.

MBX Biosciences Trading Down 10.6%

MBX Biosciences stock traded down $1.37 during midday trading on Friday, reaching $11.55. The company's stock had a trading volume of 525,960 shares, compared to its average volume of 325,620. MBX Biosciences, Inc. has a 52 week low of $4.81 and a 52 week high of $27.50. The business has a 50-day moving average price of $13.23 and a 200-day moving average price of $10.97. The stock has a market cap of $388.01 million and a PE ratio of -2.54.

Analyst Ratings Changes

MBX has been the topic of a number of research reports. Mizuho initiated coverage on MBX Biosciences in a report on Tuesday, August 5th. They issued an "outperform" rating and a $38.00 price objective on the stock. Oppenheimer started coverage on shares of MBX Biosciences in a research report on Wednesday, July 16th. They set an "outperform" rating and a $38.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat, MBX Biosciences has an average rating of "Buy" and an average target price of $37.63.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.